La bourse est fermée
  • Dow Jones

    33 683,98
    -61,42 (-0,18 %)
     
  • Nasdaq

    13 981,31
    +131,31 (+0,95 %)
     
  • Nikkei 225

    29 751,61
    +212,88 (+0,72 %)
     
  • EUR/USD

    1,1947
    +0,0030 (+0,25 %)
     
  • HANG SENG

    28 497,25
    +43,97 (+0,15 %)
     
  • BTC-EUR

    52 750,34
    +2 211,70 (+4,38 %)
     
  • CMC Crypto 200

    1 348,27
    +54,28 (+4,19 %)
     
  • S&P 500

    4 142,22
    +14,23 (+0,34 %)
     

Global Urolithiasis Management Devices Market to Reach $2.1 Billion by 2027

ReportLinker
·26 min de lecture

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 7. - Influencer Pool: 1216. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 10, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Urolithiasis Management Devices Industry" - https://www.reportlinker.com/p06033203/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

  • Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

  • Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

  • Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

  • Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

  • Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.



Abstract:
- Global Urolithiasis Management Devices Market to Reach $2.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Urolithiasis Management Devices estimated at US$1.5 Billion in the year 2020, is projected to reach a revised size of US$2.1 Billion by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027. Extracorporeal Shock Wave Lithotripsy (ESWL), one of the segments analyzed in the report, is projected to record a 4.4% CAGR and reach US$842.5 Million by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Intracorporeal Lithotripsy segment is readjusted to a revised 4.9% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $416.7 Million, While China is Forecast to Grow at 7.4% CAGR
- The Urolithiasis Management Devices market in the U.S. is estimated at US$416.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$437.9 Million by the year 2027 trailing a CAGR of 7.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.6% and 3.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.
- Percutaneous Nephrolithotomy Segment to Record 4.6% CAGR
- In the global Percutaneous Nephrolithotomy segment, USA, Canada, Japan, China and Europe will drive the 4.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$254.8 Million in the year 2020 will reach a projected size of US$343.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$283.1 Million by the year 2027, while Latin America will expand at a 5% CAGR through the analysis period.

Select Competitors (Total 42 Featured) -

  • Boston Scientific

  • Cook Medical

  • Cybersonics

  • Direxgroup

  • Dornier

  • Dornier

  • Elmed

  • Karl Storz

  • MTS Medical

  • Olympus




Read the full report: https://www.reportlinker.com/p06033203/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
Urolithiasis Management Devices Competitor Market Share
Scenario Worldwide (in %): 2020E
Global Competitor Market Shares by Segment

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Urolithiasis
Management Devices by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Urolithiasis Management
Devices by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Urolithiasis Management
Devices by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2012,
2020 & 2027

Table 4: World Current & Future Analysis for Extracorporeal
Shock Wave Lithotripsy (ESWL) by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Extracorporeal Shock Wave
Lithotripsy (ESWL) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Extracorporeal Shock
Wave Lithotripsy (ESWL) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 7: World Current & Future Analysis for Intracorporeal
Lithotripsy by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Intracorporeal Lithotripsy
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Intracorporeal
Lithotripsy by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 10: World Current & Future Analysis for Percutaneous
Nephrolithotomy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Percutaneous
Nephrolithotomy by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Percutaneous
Nephrolithotomy by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 13: World Current & Future Analysis for Other Treatment
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Other Treatment Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Other Treatment Types
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Hospitals &
Clinics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Hospitals & Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Hospitals & Clinics by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Ambulatory
Surgical Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Ambulatory Surgical Centers
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Ambulatory Surgical
Centers by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

III. MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
Market Analytics
Table 22: USA Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 23: USA Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 24: USA 15-Year Perspective for Urolithiasis Management
Devices by Treatment Type - Percentage Breakdown of Value Sales
for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 25: USA Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 26: USA Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: USA 15-Year Perspective for Urolithiasis Management
Devices by End-Use - Percentage Breakdown of Value Sales for
Hospitals & Clinics and Ambulatory Surgical Centers for the
Years 2012, 2020 & 2027

CANADA
Table 28: Canada Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 29: Canada Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 30: Canada 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of
Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 31: Canada Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 32: Canada Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: Canada 15-Year Perspective for Urolithiasis
Management Devices by End-Use - Percentage Breakdown of Value
Sales for Hospitals & Clinics and Ambulatory Surgical Centers
for the Years 2012, 2020 & 2027

JAPAN
Table 34: Japan Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 35: Japan Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 36: Japan 15-Year Perspective for Urolithiasis Management
Devices by Treatment Type - Percentage Breakdown of Value Sales
for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 37: Japan Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 38: Japan Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: Japan 15-Year Perspective for Urolithiasis Management
Devices by End-Use - Percentage Breakdown of Value Sales for
Hospitals & Clinics and Ambulatory Surgical Centers for the
Years 2012, 2020 & 2027

CHINA
Table 40: China Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 41: China Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 42: China 15-Year Perspective for Urolithiasis Management
Devices by Treatment Type - Percentage Breakdown of Value Sales
for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 43: China Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 44: China Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: China 15-Year Perspective for Urolithiasis Management
Devices by End-Use - Percentage Breakdown of Value Sales for
Hospitals & Clinics and Ambulatory Surgical Centers for the
Years 2012, 2020 & 2027

EUROPE
Market Facts & Figures
Market Analytics
Table 46: Europe Current & Future Analysis for Urolithiasis
Management Devices by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 47: Europe Historic Review for Urolithiasis Management
Devices by Geographic Region - France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2012 through 2019 and
% CAGR

Table 48: Europe 15-Year Perspective for Urolithiasis
Management Devices by Geographic Region - Percentage Breakdown
of Value Sales for France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 49: Europe Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 50: Europe Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 51: Europe 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of
Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 52: Europe Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 53: Europe Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Europe 15-Year Perspective for Urolithiasis
Management Devices by End-Use - Percentage Breakdown of Value
Sales for Hospitals & Clinics and Ambulatory Surgical Centers
for the Years 2012, 2020 & 2027

FRANCE
Table 55: France Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 56: France Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 57: France 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of
Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 58: France Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 59: France Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: France 15-Year Perspective for Urolithiasis
Management Devices by End-Use - Percentage Breakdown of Value
Sales for Hospitals & Clinics and Ambulatory Surgical Centers
for the Years 2012, 2020 & 2027

GERMANY
Table 61: Germany Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 62: Germany Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 63: Germany 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of
Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 64: Germany Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 65: Germany Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Germany 15-Year Perspective for Urolithiasis
Management Devices by End-Use - Percentage Breakdown of Value
Sales for Hospitals & Clinics and Ambulatory Surgical Centers
for the Years 2012, 2020 & 2027

ITALY
Table 67: Italy Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 68: Italy Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 69: Italy 15-Year Perspective for Urolithiasis Management
Devices by Treatment Type - Percentage Breakdown of Value Sales
for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 70: Italy Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 71: Italy Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Italy 15-Year Perspective for Urolithiasis Management
Devices by End-Use - Percentage Breakdown of Value Sales for
Hospitals & Clinics and Ambulatory Surgical Centers for the
Years 2012, 2020 & 2027

UNITED KINGDOM
Table 73: UK Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 74: UK Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 75: UK 15-Year Perspective for Urolithiasis Management
Devices by Treatment Type - Percentage Breakdown of Value Sales
for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 76: UK Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 77: UK Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: UK 15-Year Perspective for Urolithiasis Management
Devices by End-Use - Percentage Breakdown of Value Sales for
Hospitals & Clinics and Ambulatory Surgical Centers for the
Years 2012, 2020 & 2027

SPAIN
Table 79: Spain Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 80: Spain Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 81: Spain 15-Year Perspective for Urolithiasis Management
Devices by Treatment Type - Percentage Breakdown of Value Sales
for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 82: Spain Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 83: Spain Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: Spain 15-Year Perspective for Urolithiasis Management
Devices by End-Use - Percentage Breakdown of Value Sales for
Hospitals & Clinics and Ambulatory Surgical Centers for the
Years 2012, 2020 & 2027

RUSSIA
Table 85: Russia Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 86: Russia Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 87: Russia 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of
Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 88: Russia Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 89: Russia Historic Review for Urolithiasis Management
Devices by End-Use - Hospitals & Clinics and Ambulatory
Surgical Centers Markets - Independent Analysis of Annual Sales
in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 90: Russia 15-Year Perspective for Urolithiasis
Management Devices by End-Use - Percentage Breakdown of Value
Sales for Hospitals & Clinics and Ambulatory Surgical Centers
for the Years 2012, 2020 & 2027

REST OF EUROPE
Table 91: Rest of Europe Current & Future Analysis for
Urolithiasis Management Devices by Treatment Type -
Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal
Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 92: Rest of Europe Historic Review for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2012 through 2019 and % CAGR

Table 93: Rest of Europe 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of
Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 94: Rest of Europe Current & Future Analysis for
Urolithiasis Management Devices by End-Use - Hospitals &
Clinics and Ambulatory Surgical Centers - Independent Analysis
of Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 95: Rest of Europe Historic Review for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 96: Rest of Europe 15-Year Perspective for Urolithiasis
Management Devices by End-Use - Percentage Breakdown of Value
Sales for Hospitals & Clinics and Ambulatory Surgical Centers
for the Years 2012, 2020 & 2027

ASIA-PACIFIC
Table 97: Asia-Pacific Current & Future Analysis for
Urolithiasis Management Devices by Geographic Region -
Australia, India, South Korea and Rest of Asia-Pacific Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 98: Asia-Pacific Historic Review for Urolithiasis
Management Devices by Geographic Region - Australia, India,
South Korea and Rest of Asia-Pacific Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 99: Asia-Pacific 15-Year Perspective for Urolithiasis
Management Devices by Geographic Region - Percentage Breakdown
of Value Sales for Australia, India, South Korea and Rest of
Asia-Pacific Markets for Years 2012, 2020 & 2027

Table 100: Asia-Pacific Current & Future Analysis for
Urolithiasis Management Devices by Treatment Type -
Extracorporeal Shock Wave Lithotripsy (ESWL), Intracorporeal
Lithotripsy, Percutaneous Nephrolithotomy and Other Treatment
Types - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 101: Asia-Pacific Historic Review for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2012 through 2019 and % CAGR

Table 102: Asia-Pacific 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of
Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 103: Asia-Pacific Current & Future Analysis for
Urolithiasis Management Devices by End-Use - Hospitals &
Clinics and Ambulatory Surgical Centers - Independent Analysis
of Annual Sales in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 104: Asia-Pacific Historic Review for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 105: Asia-Pacific 15-Year Perspective for Urolithiasis
Management Devices by End-Use - Percentage Breakdown of Value
Sales for Hospitals & Clinics and Ambulatory Surgical Centers
for the Years 2012, 2020 & 2027

AUSTRALIA
Table 106: Australia Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 107: Australia Historic Review for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types Markets -
Independent Analysis of Annual Sales in US$ Thousand for
Years 2012 through 2019 and % CAGR

Table 108: Australia 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of
Value Sales for Extracorporeal Shock Wave Lithotripsy (ESWL),
Intracorporeal Lithotripsy, Percutaneous Nephrolithotomy and
Other Treatment Types for the Years 2012, 2020 & 2027

Table 109: Australia Current & Future Analysis for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers - Independent Analysis of Annual
Sales in US$ Thousand for the Years 2020 through 2027 and %
CAGR

Table 110: Australia Historic Review for Urolithiasis
Management Devices by End-Use - Hospitals & Clinics and
Ambulatory Surgical Centers Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2012 through 2019 and %
CAGR

Table 111: Australia 15-Year Perspective for Urolithiasis
Management Devices by End-Use - Percentage Breakdown of Value
Sales for Hospitals & Clinics and Ambulatory Surgical Centers
for the Years 2012, 2020 & 2027

INDIA
Table 112: India Current & Future Analysis for Urolithiasis
Management Devices by Treatment Type - Extracorporeal Shock
Wave Lithotripsy (ESWL), Intracorporeal Lithotripsy,
Percutaneous Nephrolithotomy and Other Treatment Types -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 113: India Historic Review for Urolithiasis Management
Devices by Treatment Type - Extracorporeal Shock Wave
Lithotripsy (ESWL), Intracorporeal Lithotripsy, Percutaneous
Nephrolithotomy and Other Treatment Types Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2012 through
2019 and % CAGR

Table 114: India 15-Year Perspective for Urolithiasis
Management Devices by Treatment Type - Percentage Breakdown of

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06033203/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001